- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02083068
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Обзор исследования
Статус
Условия
Подробное описание
This study is a prospective controlled, blinded clinical trial, designed to establish the protective efficacy induced by the vaccine PvCSP between human volunteers with and without history of malaria.
Study subjects
This study will require the involvement of two types of volunteers:
- Parasite donors: 5-15 P. vivax-infected patients who will serve as parasites donors for experimental infection of mosquitoes, who will be enrolled in the endemic area.
- Volunteers for immunization: Two other groups of volunteers will be immunized with the vaccine PvCSP. A group of 16 people without previous exposure to malaria (naive) and another 16 people with a history of previous malaria infection (pre-immune).
Methodology Recruitment of infected patients: Parasite donors will be recruited among P. vivax infected patients attending a diagnostic center in the endemic area.
Infection of mosquitoes Blood from donors will be used to feed three days old mosquitoes by artificial membrane feeding technique. At day 7 a sample of mosquitoes will be examined to determine the degree of infection by dissection of the mosquito gut. On day 14, a small amount of mosquitoes with a good degree of infectivity will be used to infect challenged volunteers.
Recruitment of pre-immune and naive volunteers: Volunteers for the immunization stage will be recruited both in the city of Cali, non-endemic region, and in Buenaventura, a malaria endemic region, through various activities such as conferences, meetings and other means approved by the IRB like posters and flyers.
Immunization: Volunteers will be immunized with the vaccine (n=16) or placebo (n=16).
Follow Up Volunteers will be under medical vigilance during the first hour following the immunization to detect any adverse reaction. After the first hour period a medical exam will be made. Eight hours after immunization, each volunteer will be telephoned to assess physical condition. Any adverse event (AE) will be registered.
Subsequent follow up will be made on the day next to immunization and 1 or 2 weeks before the next immunization by a new clinical evaluation and AE report. Volunteers will be educated to contact the research staff at any moment.
Infection of volunteers Immunized volunteers will be challenged on day ~150 of the study, 1 month after the third immunization by the bite of 3±1 infected mosquitos. The "feeding cage" will be placed on the forearm of a volunteer for 10 minutes, allowing that the feeding window, wich will be covered by a mesh surface be placed against the volunteer's skin.
Volunteers will be educated about the signs and symptoms of malaria and they will have a daily telephone contact during the first 6 days.
Between days 7 and 23 the volunteers will be asked to go to the Clinical Trials Unit daily in order to establish the presence or absence of disease through thick blood smear and samples will be collected for retrospective real time PCR P. vivax.
From day 23 until day 31, volunteers will receive physical and laboratory evaluation every other day and will have daily telephone contact.
Once the patients present signs and symptoms of the disease curative treatment will be immediately provided, and 15 ml of blood will be drawn, which will be used for immune response assessment.
If the volunteers do not develop the disease during the follow-up period, on day 31 they will be given antimalarial treatment.
Treatment Volunteers will be treated with antimalarial drugs approved by the Colombian Ministry of Social Protection: chloroquine (three (3) doses: 600 mg initially, followed by 450mg at 24, and 48 hours), associated with primaquine (30mg/día) for 14 days. All the volunteers will be asked to return two weeks after starting treatment for a thick blood smear test to ensure cure of malaria.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Колумбия
- Malaria Vaccine and Drug Development Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Naïve group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign.
Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) > 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study
2. Preimmune group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign .
Having a history of infection (s ) and serological tests for malaria positive for P. vivax.
For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .
Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study.
3. Voluntary blood donors
- Healthy men and women aged 18-45 years.
- Be positive diagnosis of P. vivax determined by thick smear examination .
- The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .
- Have a parasitemia ≥ 0.1 %. by thick smear .
- Hb ≥ 9 g / dL at the time of diagnosis of malaria.
- The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign
Exclusion Criteria:
Step 1
- Negative IFAT (< 1:20) for P. vivax on screening tests
- Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.
Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.
Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Фундаментальная наука
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Experimental
10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
|
Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015
At month 2 and 6
Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015,
at month 0
|
Плацебо Компаратор: Control
six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
|
SSN Montanide ISA-51 1 mL
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
Временное ограничение: Thirty days after the last immunization
|
Vaccine protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
|
Thirty days after the last immunization
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Evolution of antibody titers
Временное ограничение: At months 0, 2, 4 and 6 of the trial
|
Follow up every 2 months (month 0, 2, 4 and 6) until the end of the trial will be done to assess the evolution of P. vivax antibody titers.
|
At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction
Временное ограничение: At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10
|
At months 0, 2, 4 and 6 of the trial
|
Changes on vaccine biological security
Временное ограничение: On the day next to immunization and 1 or 2 weeks before the next immunization
|
Changes on vaccine biological security will be measured by renal, hepatic and hematologic function and pregnancy test.
|
On the day next to immunization and 1 or 2 weeks before the next immunization
|
Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
Временное ограничение: Every 2 months
|
Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
|
Every 2 months
|
Vaccine-induced protection for P. vivax
Временное ограничение: 28 days after mosquito bites
|
Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure
|
28 days after mosquito bites
|
Соавторы и исследователи
Публикации и полезные ссылки
Общие публикации
- Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, Palacios R, Ramirez O, Velez JD, Epstein JE, Richie TL, Arevalo-Herrera M. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11. doi: 10.4269/ajtmh.2011.09-0498.
- Arevalo-Herrera M, Gaitan X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Onate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat Commun. 2022 Mar 25;13(1):1603. doi: 10.1038/s41467-022-29226-3.
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 2304-493-26202
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Vaccine PvCS N+C+R
-
Malaria Vaccine and Drug Development CenterAsoclinic Inmunología Ltda.; Centro médico ImbanacoЗавершенный
-
CHDI Foundation, Inc.Universitaire Ziekenhuizen KU LeuvenПрекращено
-
TidalSenseNational Institute for Health Research, United Kingdom; Innovate UKЗавершенныйЗдоровый | Бронхоэктазы | Анемия | Астма | Рак легких | Интерстициальное заболевание легких | ХОБЛ | Долгий COVID | Болезнь верхних дыхательных путей | Застойная сердечная недостаточностьСоединенное Королевство
-
Universidad Nacional Autonoma de MexicoРекрутингТеленейропсихологическое вмешательство у бессимптомных ВИЧ-серопозитивных пациентов: N&C NeuroChangeТелереабилитация | Нейропсихология | ВИЧ-деменцияМексика
-
NYU Langone HealthNational Eye Institute (NEI)ЗавершенныйГлаукома | Глазные болезни | Возрастная дегенерация желтого пятна | Диабетическая ретинопатия | Центральная серозная хориоретинопатия | Глаукома, подозрениеСоединенные Штаты
-
Medical University of ViennaРекрутингГиперемезис беременных | Тошнота беременных | Дефицит витамина САвстрия
-
Omaima Mossad Mahmoud AL-SherbiniЗавершенныйБоль, Послеоперационный | Рецессия десны | Удовлетворенность пациентов | Донорский сайт | Открытая рана неба без осложнений | Бесплатные десневые трансплантаты | Мукогингивальные дефектыЕгипет
-
Indiana University School of MedicineПрекращеноПрофилактика инфекцийСоединенные Штаты
-
Children's Oncology GroupNational Cancer Institute (NCI)ЗавершенныйСаркома | Опухоли головного мозга и центральной нервной системы | НейробластомаСоединенные Штаты, Канада, Пуэрто-Рико, Нидерланды, Австралия, Новая Зеландия, Швейцария
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalНеизвестныйРак молочной железы у женщинТайвань, Корея, Республика, Италия